Riccardo Paolo Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Riccardo Paolo Russo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aparna Raychaudhuri
GlaxoSmithKline Pharmaceuticals, Collegeville, PA, USA
1 shared publication - Charles Jakielaszek
Infectious Diseases Research, GSK
1 shared publication - Cindy Fishman
GSK, Collegeville, PA, USA
1 shared publication - David Revelli
Lovelace Biomedical Research Institute, USA
1 shared publication - Edoardo Bardi
Department of Veterinary Medicine, University of Milan, Via dell’Università 6, 26900 Lodi, Italy
1 shared publication Elisabeth Carniel
Yersinia Research Unit, Institut Pasteur, Paris France
1 shared publication
Latest Publications
- 1 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (647) , eabg1787
Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .
- 1 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (647) , eabg1787
Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .
- Open Access
- 1 October 2021
- Published by Elsevier in Journal of Exotic Pet Medicine
- Vol. 39, 78-80
Use of intralipid emulsion therapy to treat suspected oleander toxicosis in a domestic goose (Anser anser domesticus)
- 1 October 2021
- Published by Elsevier in Journal of Exotic Pet Medicine
- Vol. 39, 78-80
Open AccessUse of intralipid emulsion therapy to treat suspected oleander toxicosis in a domestic goose (Anser anser domesticus)